21% Response Rate for Previously Treated Melanoma Using Nivolumab and Ipilimumab - 102126

Spotlight
Video

21% Response Rate for Previously Treated Melanoma Using Nivolumab and Ipilimumab

Loading........
Description: Claire Friedman, MD of Memorial-Sloan Kettering discusses the use of combination therapy for patients with melanoma at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Shared By : AnnualMeeting-SITC2017
Posted on : 03/06/17
Added : 1 year ago